General MedicationsINJECTIONGeneric

AMPICILLIN SODIUM

Standard Dose

EQ 500MG BASE/VIAL

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview AMPICILLIN SODIUM is listed in Drugs@FDA under application 202864 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient AMPICILLIN SODIUM Form and strength INJECTABLE;INJECTION - EQ 500MG BASE/VIAL Sponsor HOSPIRA Submission history Latest submission status date: 2018-02-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview AMPICILLIN SODIUM is listed in Drugs@FDA under application 202864 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient AMPICILLIN SODIUM Form and strength INJECTABLE;INJECTION - EQ 500MG BASE/VIAL Sponsor HOSPIRA Submission history Latest submission status date: 2018-02-15 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.